XML 58 R47.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Acquisitions (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Jul. 05, 2016 | Sep. 30, 2015 | Apr. 30, 2016 | Nov. 30, 2013 | Jun. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  | $ 269,722 | $ 274,077 |
Contingent consideration payable, current portion |  |  |  |  |  | 56,101 | 41,400 |
Changes in fair value of contingent consideration payable |  |  |  |  |  | 6,760 | 4,377 | $ 100
Payment of contingent consideration in stock, impact on stockholder's equity |  |  |  |  |  | 6,115 |  |
Scioderm |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Initial amount to Effective Time Holders |  | $ 223,900 |  |  |  |  |  |
Initial amount cash payment excluding Series B Preferred |  | 141,100 |  |  |  |  |  |
Initial amount paid in shares of Common Stock |  | $ 82,800 |  |  |  |  |  |
Priority review voucher transfer years |  | 1 year |  |  |  |  |  |
Payment to be made if Priority Review Voucher is obtained and used |  | $ 100,000 |  |  |  |  |  |
Contingent consideration payable |  | 259,000 |  |  |  | 260,000 |  |
Contingent consideration payable, current portion |  |  |  |  |  | 56,100 |  |
Scioderm | Changes in fair value of contingent consideration payable |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Changes in fair value of contingent consideration payable |  |  |  |  |  | 7,300 |  |
Scioderm | IPR&D |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Intangible assets-IPR&D |  |  |  |  |  |  | $ 463,700 |
Scioderm | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Priority Review Voucher sale proceeds shared |  | $ 100,000 |  |  |  |  |  |
Priority Review Voucher sale proceeds shared (as a percent) |  | 50.00% |  |  |  |  |  |
Scioderm | Scioderm | Series B Preferred Stock |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Consideration paid in common stock |  | 5,900,000 |  |  |  |  |  |
Callidus |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | $ 10,600 |  | 9,700 |  |
Discount rate (as a percent) |  |  |  | 13.50% |  |  |  |
Milestone payment, value of shares issued |  |  |  |  | $ 6,000 |  |  |
Payment of contingent consideration in stock, impact on stockholder's equity |  |  |  |  | 6,100 |  |  |
Callidus | Changes in fair value of contingent consideration payable |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Changes in fair value of contingent consideration payable |  |  |  |  |  | (500) |  |
MiaMed Inc |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Total consideration, stock and cash | $ 6,500 |  |  |  |  |  |  |
Cash consideration paid | 1,800 |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | 83,000 |  |  |  |  |  |  |
Potential aggregate deal value | 89,500 |  |  |  |  |  |  |
Research and development expense | $ 6,500 |  |  |  |  |  |  |
MiaMed Inc | Amicus | Common Stock |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Consideration paid in common stock | 825,603 |  |  |  |  |  |  |
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | $ 83,000 |  |  |  |  |  |  |
Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  | 237,200 |  |
Milestone payment |  |  |  |  | $ 5,000 |  |  |
Clinical and Regulatory Approval milestones | Scioderm | Minimum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 0.40% |  |  |  |  |  |
Clinical and Regulatory Approval milestones | Scioderm | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Upfront cash payments |  | $ 361,000 | $ 361,000 |  |  |  |  |
Discount rate (as a percent) |  | 1.10% |  |  |  |  |  |
Clinical and Regulatory Approval milestones | Callidus |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  | 9,300 |  |
Revenue-based milestones | Scioderm |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Upfront equity payments |  | $ 257,000 |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  | 22,800 |  |
Revenue-based milestones | Scioderm | Minimum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 1.00% |  |  |  |  |  |
Revenue-based milestones | Scioderm | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Upfront equity payments |  |  |  |  |  | $ 257,000 |  |
Discount rate (as a percent) |  | 2.20% |  |  |  |  |  |
Clinical milestone | Scioderm | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Upfront cash payments |  |  | 81,000 |  |  |  |  |
Regulatory Approval milestone | Scioderm | Maximum |  |  |  |  |  |  |  |
Acquisitions |  |  |  |  |  |  |  |
Upfront cash payments |  |  | $ 280,000 |  |  |  |  |

X
- Definition The cash outflow associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement. + References No definition available. + Details
Name: | fold_BusinessCombinationAdjustedCashConsiderationTransferred
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, adjusted to excluding the exercise price of outstanding acquiree options and warrants and acquiree cash and cash equivalents. + References No definition available. + Details
Name: | fold_BusinessCombinationAdjustedConsiderationTransferred
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the value of Common Stock outflow or payments associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement. + References No definition available. + Details
Name: | fold_BusinessCombinationAdjustedEquityConsiderationTransferred
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessCombinationContingentConsiderationMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold. + References No definition available. + Details
Name: | fold_BusinessCombinationPriorityReviewVoucherSalePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold. + References No definition available. + Details
Name: | fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the payment that will be made to qualifying equity holders of the acquired entity in the event that the Priority Review Voucher is obtained and used. + References No definition available. + Details
Name: | fold_BusinessCombinationPriorityReviewVoucherUsedPayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payment. + References No definition available. + Details
Name: | fold_ContingentConsiderationMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of contingent consideration liability in stock during the period. + References No definition available. + Details
Name: | fold_ContingentConsiderationPaidInStock
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of years of Priority Review Voucher sale transfer to third party. + References No definition available. + Details
Name: | fold_PriorityReviewVoucherTransferYears
Namespace Prefix: | fold_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of shares issued for noncash contingent consideration upon achieving event based milestones. + References No definition available. + Details
Name: | fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |